Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Study of Botensilimab Plus Balstilimab and Fasting-Mimicking Diet (FMD) Plus Vitamin C in Patients With KRAS-Mutant Metastatic Colorectal Cancer

NCT06336902 is registered in ClinicalTrials.gov with University of Southern California as lead sponsor.

NCT NCT06336902
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06336902 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Study of Botensilimab Plus Balstilimab and Fasting-Mimicking Diet (FMD) Plus Vitamin C in Patients With KRAS-Mutant Metastatic Colorectal Cancer
Lead sponsor
University of Southern California
Phase
Phase 1
Overall status
Recruiting
Start date
January 15, 2025
Completion date
January 15, 2028
Enrollment
15 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal adenocarcinoma, stage iv colorectal cancer ajcc v8